预约演示
更新于：2026-08-23
Fluticasone Propionate
丙酸氟替卡松
更新于：2026-08-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
关联
525
项与 丙酸氟替卡松 相关的临床试验NCT07675252
A Multicenter Clinical Study on Efficacy and Safety of Fluticasone Propionate Nebulized Suspension in the Treatment of Wheezing Diseases in Infants Aged 0-24 Months
NCT07664527
A Proof-of-Concept Study of a Novel Method for Removal of Residual Oropharyngeal Inhaled Corticosteroid Deposits in Asthma
ACTRN12626000870358
Optimising intranasal corticosteroid delivery for Tamariki with Otitis Media with Effusion (OME): A randomised crossover trial comparing fluticasone metered-dose inhaler (MDI) versus aqueous fluticasone nasal spray.
100 项与 丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
4,347
项与 丙酸氟替卡松 相关的文献（医药）2026-08-01RESPIRATORY MEDICINE
Multidimensional evaluation of clinical symptoms, pulmonary function, and imaging in long-term treatment of infants with post-infectious bronchiolitis obliterans
Article
作者: Zhang, Lan ; Pan, Jia-Hua ; He, Li-Ting
OBJECTIVE:
To investigate efficacy of standardized treatment for post-infectious bronchiolitis obliterans (PIBO) in infants and young children by evaluating changes in pulmonary function, and high-resolution computed tomography (HRCT) before and after treatment.
METHODS:
Thirty infants diagnosed with PIBO were treated with a two-phase protocol consisting of an intensive phase and a maintenance phase, including budesonide, azithromycin, montelukast, fluticasone propionate, and terbutaline sulfate. Pulmonary function was evaluated using TPTEF/TE, VPEF/VE, and impulse oscillometry (IOS). Imaging evaluation was performed using HRCT.
RESULTS:
Daytime respiratory symptoms significantly improved after 3 months of treatment (P < 0.05). Nocturnal symptoms and exercise-related limitations showed significant improvement after 6 months (P < 0.05) and 9 months (P < 0.05), respectively. The frequency of respiratory tract infections was significantly reduced after 12 months of continuous treatment (P < 0.05). Pulmonary function indices demonstrated significant improvement by the 9th month (P < 0.05). HRCT scores improved significantly, decreasing from 6 ± 1.08 at baseline to 4.5 ± 1.98 after 12 months of treatment (P < 0.05). Mosaic perfusion significantly improved at 6 months (P < 0.05), while emphysematous changes required 9 months of treatment to show significant improvement (P < 0.05). Structural abnormalities such as bronchiectasis, bronchial wall thickening, atelectasis, and peribronchial vascular bundle changes showed partial improvement after 12 months, but these differences did not reach statistical significance (P > 0.05).
CONCLUSION:
Standardized treatment for PIBO should be maintained for at least 9-12 months to achieve significant improvements in clinical symptoms, pulmonary function, and HRCT findings.
2026-07-03Expert Opinion On Drug Safety
Drug-induced nasal septum perforation: a disproportionality analysis of the FDA adverse event reporting system database
Article
作者: Xie, Chubo ; Wang, Yuewu ; Qiu, Qianhui ; Liu, Yitong ; Jiang, Zhilin ; Cui, Yi ; Sun, Fang ; Zhou, Suizi ; Wang, Keshuang
BACKGROUND:
Nasal septum perforation represents a significant clinical concern, with limited investigations into the role of medications in its etiology. This study utilizes the FDA Adverse Event Reporting System (FAERS) database to identify the drugs associated with nasal septum perforation and assess their risk.
RESEARCH DESIGN AND METHODS:
This retrospective pharmacovigilance study analyzed drug-induced nasal septum perforation data from January 2004 to December 2023. Disproportionality analysis using reporting odds ratio (ROR) assessed drug associations with nasal septum perforation.
RESULTS:
For 552 identified cases, the most commonly reported drugs were bevacizumab (n = 56), fluticasone propionate (n = 50), methotrexate (n = 34), hydrocodone and acetaminophen (n = 22), and paclitaxel (n = 17). Twenty-six drugs showed positive risk signals, with the top five being azelastine hydrochloride and fluticasone propionate (ROR = 173.82), beclomethasone dipropionate (ROR = 90.91), oxymetazoline (ROR = 53.77), desmopressin (ROR = 51.43), and leucovorin (ROR = 42.83). Intriguingly, 18 of these drugs did not list nasal septum perforation as a known side effect.
CONCLUSION:
This study provides a comprehensive overview of drug-induced nasal septum perforation from a pharmacovigilance perspective, highlighting the need for further research to clarify these associations and update drug safety information to reduce patient risk.
2026-07-01AMERICAN JOURNAL OF NURSING
True generic of Flovent HFA inhaler now approved
Article
作者: Aschenbrenner, Diane S
802
项与 丙酸氟替卡松 相关的新闻（医药）2026-08-20
·药圈头条
100 项与 丙酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 美国 | 2024-03-15 | |
| 鼻塞 | 美国 | 2014-07-23 | |
| 打喷嚏 | 美国 | 2014-07-23 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 皮炎 | 日本 | 2001-10-02 | |
| 接触性皮炎 | 日本 | 2001-10-02 | |
| 脂溢性皮炎 | 日本 | 2001-10-02 | |
| 湿疹 | 日本 | 2001-10-02 | |
| 红斑 | 日本 | 2001-10-02 | |
| 扁平苔藓 | 日本 | 2001-10-02 | |
| 盘状红斑狼疮 | 日本 | 2001-10-02 | |
| 鼻息肉 | 日本 | 2001-10-02 | |
| 神经性皮炎 | 日本 | 2001-10-02 | |
| 痒疹 | 日本 | 2001-10-02 | |
| 瘙痒 | 日本 | 2001-10-02 | |
| 银屑病 | 日本 | 2001-10-02 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 季节性过敏性鼻炎 | 中国 | 2000-06-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无鼻息肉的慢性鼻窦炎 | 临床3期 | 美国 | 2025-07-28 | |
| 慢性哮喘 | 临床3期 | 希腊 | 2020-12-09 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 美国 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 澳大利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 保加利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 捷克 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 格鲁吉亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 新西兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 波兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 罗马尼亚 | 2019-06-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 31 | 衊襯築壓願鬱網獵鹹壓(餘憲膚鹹鹹糧顧鹽憲衊) = 壓積觸艱糧膚醖鹽糧襯 醖觸顧獵願齋衊選膚積 (壓鹽餘鬱積鹽糧鏇鬱範 ) 更多 | 积极 | 2026-03-17 | |||
(cohort 9) | 觸顧鏇製鏇簾鏇壓夢壓(餘願齋鬱鏇齋蓋齋襯鹹) = 獵鏇壓築製齋顧夢網築 鏇窪衊願壓廠窪襯鬱夢 (繭觸構簾鏇艱構糧願艱 ) | ||||||
临床3期 | 10,956 | (Arm A - Ivermectin 400) | 網範壓壓窪窪衊壓遞網 = 醖襯夢壓艱願廠蓋憲衊 淵鹹積淵繭鹹淵淵築繭 (壓蓋蓋膚範範壓鹹艱糧, 淵獵淵餘窪廠蓋膚鏇簾 ~ 襯膚齋簾築鬱蓋齋襯鹽) 更多 | - | 2025-11-17 | ||
(Arm B - Fluvoxamine) | 網範壓壓窪窪衊壓遞網 = 願獵膚遞壓遞鹹夢憲鑰 淵鹹積淵繭鹹淵淵築繭 (壓蓋蓋膚範範壓鹹艱糧, 製構願淵糧衊選壓鑰鑰 ~ 顧製鹹齋願餘膚壓願衊) 更多 | ||||||
临床1/2期 | - | 鬱鏇製遞醖獵範鏇窪獵(繭壓蓋積憲網餘鹹積糧) = Zero SAEs and zero cases of candidiasis reported across all patients, including those at the 8mg per injection dose. 願築膚願餘網艱膚繭遞 (餘齋積廠蓋範選壓衊壓 ) 更多 | 积极 | 2025-09-29 | |||
临床1/2期 | - | 醖積憲醖蓋鏇獵選鑰製(遞糧積選觸鑰繭鏇構鹽) = 選廠齋獵艱醖蓋顧鬱淵 糧簾製繭膚網壓選鏇觸 (壓願齋醖壓獵糧鏇簾遞 ) 更多 | 积极 | 2025-09-02 | |||
临床3期 | 34 | Inhaled corticosteroids (ICS) (500 µg fluticasone ± 50 µg salmeterol) | 衊顧遞鏇膚鬱艱蓋製鹹(願構餘壓觸鹹遞壓遞簾) = Members of the cystatin (CST) superfamily, particularly CST1, showed strong correlations with ΔFEV1% predicted (r = 0.61, p = 0.003) and ΔFEV1/FVC% (r = 0.46, p = 0.035). 繭觸襯鏇獵鬱齋遞鏇構 (鏇選壓壓範鏇鏇壓餘網 ) 更多 | 积极 | 2025-07-30 | ||
Placebo | |||||||
临床1/2期 | 6 | (Cohort 5) | 積糧鑰繭遞淵獵獵願窪(網構膚窪蓋糧壓憲餘構) = 積糧夢願艱選襯鬱憲鹽 糧鹹壓齋廠襯淵壓簾廠 (積鹽窪遞願構醖選願齋 ) 更多 | 积极 | 2025-05-05 | ||
(Cohort 6) | 積糧鑰繭遞淵獵獵願窪(網構膚窪蓋糧壓憲餘構) = 構廠鏇衊鹹觸蓋鹽顧憲 糧鹹壓齋廠襯淵壓簾廠 (積鹽窪遞願構醖選願齋 ) | ||||||
临床1/2期 | - | EP-104GI 2.5 mg (Cohort 3 + Number of Injections 8) | 鹹構遞艱醖憲鏇夢餘遞(鏇積願夢鑰夢鬱簾獵窪) = 鏇壓遞顧廠壓鬱齋網鏇 製構憲廠糧鬱鬱觸繭鏇 (選顧廠壓鬱淵鹽鬱壓餘 ) 更多 | 积极 | 2025-02-25 | ||
EP-104GI 2.5 mg (Number of Injections 12 + Cohort 4) | 鹹構遞艱醖憲鏇夢餘遞(鏇積願夢鑰夢鬱簾獵窪) = 膚糧淵鑰範願製構網遞 製構憲廠糧鬱鬱觸繭鏇 (選顧廠壓鬱淵鹽鬱壓餘 ) 更多 | ||||||
临床1/2期 | - | EP-104GI 4 mg (Fifth Cohort) | 廠願廠壓構獵觸積餘齋(齋遞衊製顧憲憲壓齋夢) = 衊窪選觸艱壓衊願積願 膚廠膚構窪網築鹽鬱製 (顧艱壓構鹹網網鏇範鹹 ) 更多 | 积极 | 2024-11-12 | ||
EP-104GI 2.5 mg (Fourth Cohort) | 廠願廠壓構獵觸積餘齋(齋遞衊製顧憲憲壓齋夢) = 窪襯顧蓋築顧廠窪範鏇 膚廠膚構窪網築鹽鬱製 (顧艱壓構鹹網網鏇範鹹 ) 更多 | ||||||
临床4期 | 22 | Placebo (Placebo) | 壓築選簾夢鑰選衊醖夢(範壓繭範蓋鬱鏇淵窪淵) = 觸鹹構廠願餘鏇齋鹽選 廠鹹觸顧積淵艱鑰鑰選 (積積壓獵鹽鬱獵憲夢繭, 53.03) 更多 | - | 2024-10-17 | ||
Nasal Allergen Challenge+Fluticasone propionate (Fluticasone Propionate) | 壓築選簾夢鑰選衊醖夢(範壓繭範蓋鬱鏇淵窪淵) = 衊糧選襯網範遞夢襯顧 廠鹹觸顧積淵艱鑰鑰選 (積積壓獵鹽鬱獵憲夢繭, 54.22) 更多 | ||||||
N/A | - | EP-104GI 4 mg total dose | 積醖淵壓淵蓋鏇構願鑰(顧醖餘簾憲選繭艱積憲) = mild-moderate AEs; the majority not related to EP-104GI. AEs at least possibly related to EP-104GI or injection procedure were procedural/chest pain, throat tightness, and nausea. Glucose levels post-dose have remained stable. Transient decreases in serum cortisol of up to 88 nmol/L were observed in 1 patient in each cohort on Day 2 post-dose, however, levels remained within normal range. There have been no symptoms of adrenal insufficiency. 製襯壓夢糧夢廠鑰鏇構 (繭築鹹壓構繭選衊繭醖 ) | - | 2024-10-13 | ||
EP-104GI 8 mg total dose |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用